Newborn Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Technology (Tandem Mass Spectrometry, Pulse Oximetry, Enzyme Based Assays, DNA Assays, and Other Technologies), By Test Type (Dried Blood Spot, Hearing Screening, Critical Congenital Heart Defect (CCHD), and Other Test Types), By End User (Hospitals, Diagnostic Centers, and Other End Users), By Region and Competition, 2020-2030F
Market Overview
The Global Newborn Screening Market was valued at USD 854.15 million in 2024 and is projected treach USD 1345.11 million by 2030, growing at a CAGR of 7.86% during the forecast period. This market encompasses the early detection and diagnosis of genetic, metabolic, and congenital conditions in newborns, typically within the first days after birth. As congenital disorders continue taccount for a significant share of infant morbidity and mortality globally, newborn screening has become a vital component of public healthcare systems. Increased government initiatives, advancements in screening technologies, and rising awareness regarding early disease detection have significantly boosted adoption rates. Countries are expanding their newborn screening panels tinclude a broader array of conditions, while innovations such as next-generation sequencing and tandem mass spectrometry have improved diagnostic accuracy and efficiency. The growing prevalence of congenital conditions, particularly in developing regions, is expected tsustain market growth, supported by private testing initiatives, increased healthcare spending, and global collaborations tstandardize screening practices.
Key Market Drivers
Advancements in Technology
Technological innovations have transformed newborn screening, enabling earlier and more precise detection of a wide array of conditions. Next-Generation Sequencing (NGS) facilitates simultaneous analysis of multiple genes, significantly expanding screening capabilities. It has become instrumental in identifying rare and complex genetic conditions with high accuracy. Similarly, Tandem Mass Spectrometry (MS/MS) has revolutionized metabolic screening by allowing multiple analytes tbe tested from a single sample, enabling detection of aminacid and fatty acid disorders efficiently. Multiplex assays and enhanced dried blood spot (DBS) technologies have alscontributed tthe broader and faster adoption of screening for lysosomal storage and immunodeficiency disorders. These technological advancements have reduced false positives, improved patient outcomes, and lowered healthcare costs through early interventions.
Key Market Challenges
Education and Awareness
Despite technological progress, limited public and professional awareness about the significance of newborn screening remains a substantial barrier. Many parents may lack understanding of the benefits and procedures involved, leading thesitation or refusal of screening. Inconsistent training and knowledge dissemination among healthcare professionals can further impair effective communication with families. Cultural and language differences, especially in diverse or low-resource regions, exacerbate the issue, hindering outreach and engagement. Additionally, varying policies and resource availability across countries contribute tdisparities in screening coverage and effectiveness. Efforts timprove education, standardize procedures, and address misinformation are crucial tincreasing participation and acceptance globally.
Key Market Trends
Rise in Private Testing
There is a growing trend toward private newborn screening services, as parents increasingly seek broader testing panels than those offered by public health programs. Personalized medicine, rapid result delivery, and advanced technologies are driving demand for private services. These centers offer greater autonomy and confidentiality, along with supplemental services like genetic counseling and family health planning. In regions with limited or inconsistent public programs, private testing ensures continued access tcomprehensive screening. Additionally, private providers often serve mobile populations seeking continuity of care across borders. As awareness grows and disposable incomes rise, private newborn screening is expected tgain further traction, especially in urban and high-income segments.
Key Market Players
In this report, the Global Newborn Screening Market has been segmented intthe following categories, in addition tthe industry trends which have alsbeen detailed below:
Newborn Screening Market, By Technology:
Company Profiles: Detailed analysis of the major companies present in the Global Newborn Screening Market.
Available Customizations
Global Newborn Screening Market report with the given market data, TechSci Research offers customizations according ta company's specific needs. The following customization options are available for the report:
Company Information
The Global Newborn Screening Market was valued at USD 854.15 million in 2024 and is projected treach USD 1345.11 million by 2030, growing at a CAGR of 7.86% during the forecast period. This market encompasses the early detection and diagnosis of genetic, metabolic, and congenital conditions in newborns, typically within the first days after birth. As congenital disorders continue taccount for a significant share of infant morbidity and mortality globally, newborn screening has become a vital component of public healthcare systems. Increased government initiatives, advancements in screening technologies, and rising awareness regarding early disease detection have significantly boosted adoption rates. Countries are expanding their newborn screening panels tinclude a broader array of conditions, while innovations such as next-generation sequencing and tandem mass spectrometry have improved diagnostic accuracy and efficiency. The growing prevalence of congenital conditions, particularly in developing regions, is expected tsustain market growth, supported by private testing initiatives, increased healthcare spending, and global collaborations tstandardize screening practices.
Key Market Drivers
Advancements in Technology
Technological innovations have transformed newborn screening, enabling earlier and more precise detection of a wide array of conditions. Next-Generation Sequencing (NGS) facilitates simultaneous analysis of multiple genes, significantly expanding screening capabilities. It has become instrumental in identifying rare and complex genetic conditions with high accuracy. Similarly, Tandem Mass Spectrometry (MS/MS) has revolutionized metabolic screening by allowing multiple analytes tbe tested from a single sample, enabling detection of aminacid and fatty acid disorders efficiently. Multiplex assays and enhanced dried blood spot (DBS) technologies have alscontributed tthe broader and faster adoption of screening for lysosomal storage and immunodeficiency disorders. These technological advancements have reduced false positives, improved patient outcomes, and lowered healthcare costs through early interventions.
Key Market Challenges
Education and Awareness
Despite technological progress, limited public and professional awareness about the significance of newborn screening remains a substantial barrier. Many parents may lack understanding of the benefits and procedures involved, leading thesitation or refusal of screening. Inconsistent training and knowledge dissemination among healthcare professionals can further impair effective communication with families. Cultural and language differences, especially in diverse or low-resource regions, exacerbate the issue, hindering outreach and engagement. Additionally, varying policies and resource availability across countries contribute tdisparities in screening coverage and effectiveness. Efforts timprove education, standardize procedures, and address misinformation are crucial tincreasing participation and acceptance globally.
Key Market Trends
Rise in Private Testing
There is a growing trend toward private newborn screening services, as parents increasingly seek broader testing panels than those offered by public health programs. Personalized medicine, rapid result delivery, and advanced technologies are driving demand for private services. These centers offer greater autonomy and confidentiality, along with supplemental services like genetic counseling and family health planning. In regions with limited or inconsistent public programs, private testing ensures continued access tcomprehensive screening. Additionally, private providers often serve mobile populations seeking continuity of care across borders. As awareness grows and disposable incomes rise, private newborn screening is expected tgain further traction, especially in urban and high-income segments.
Key Market Players
- Bio-Rad Laboratories Inc.
- GE Healthcare
- MasimCorporation
- Medtronic Inc.
- Natus Medical Incorporated
- PerkinElmer Inc.
- Trivitron Healthcare
- ZenTech SA
- Demant A/S
- Hill-Rom Holdings Inc.
In this report, the Global Newborn Screening Market has been segmented intthe following categories, in addition tthe industry trends which have alsbeen detailed below:
Newborn Screening Market, By Technology:
- Tandem Mass Spectrometry
- Pulse Oximetry
- Enzyme Based Assays
- DNA Assays
- Other Technologies
- Dried Blood Spot
- Hearing Screening
- Critical Congenital Heart Defect (CCHD)
- Other Test Types
- Hospitals
- Diagnostic Centers
- Other End Users
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Newborn Screening Market.
Available Customizations
Global Newborn Screening Market report with the given market data, TechSci Research offers customizations according ta company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up tfive).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. IMPACT OF COVID-19 ON GLOBAL NEWBORN SCREENING MARKET
5. VOICE OF CUSTOMER
6. GLOBAL NEWBORN SCREENING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology (Tandem Mass Spectrometry, Pulse Oximetry, Enzyme Based Assays, DNA Assays, and Other Technologies)
6.2.2. By Test Type (Dried Blood Spot, Hearing Screening, Critical Congenital Heart Defect (CCHD), and Other Test Types)
6.2.3. By End User (Hospitals, Diagnostic Centers, and Other End Users),
6.2.4. By Region
6.2.5. By Company (2024)
6.3. Market Map
7. ASIA PACIFIC NEWBORN SCREENING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Test Type
7.2.3. By End User
7.2.4. By Country
7.3. Asia Pacific: Country Analysis
7.3.1. China Newborn Screening Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Test Type
7.3.1.2.3. By End User
7.3.2. India Newborn Screening Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Test Type
7.3.2.2.3. By End User
7.3.3. Australia Newborn Screening Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Test Type
7.3.3.2.3. By End User
7.3.4. Japan Newborn Screening Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Test Type
7.3.4.2.3. By End User
7.3.5. South Korea Newborn Screening Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Test Type
7.3.5.2.3. By End User
8. EUROPE NEWBORN SCREENING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Test Type
8.2.3. By End User
8.2.4. By Country
8.3. Europe: Country Analysis
8.3.1. France Newborn Screening Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Test Type
8.3.1.2.3. By End User
8.3.2. Germany Newborn Screening Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Test Type
8.3.2.2.3. By End User
8.3.3. Spain Newborn Screening Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Test Type
8.3.3.2.3. By End User
8.3.4. Italy Newborn Screening Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Test Type
8.3.4.2.3. By End User
8.3.5. United Kingdom Newborn Screening Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Test Type
8.3.5.2.3. By End User
9. NORTH AMERICA NEWBORN SCREENING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Test Type
9.2.3. By End User
9.2.4. By Country
9.3. North America: Country Analysis
9.3.1. United States Newborn Screening Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Test Type
9.3.1.2.3. By End User
9.3.2. Mexico Newborn Screening Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Test Type
9.3.2.2.3. By End User
9.3.3. Canada Newborn Screening Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Test Type
9.3.3.2.3. By End User
10. SOUTH AMERICA NEWBORN SCREENING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Test Type
10.2.3. By End User
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Newborn Screening Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Test Type
10.3.1.2.3. By End User
10.3.2. Argentina Newborn Screening Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Test Type
10.3.2.2.3. By End User
10.3.3. Colombia Newborn Screening Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Test Type
10.3.3.2.3. By End User
11. MIDDLE EAST AND AFRICA NEWBORN SCREENING MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Technology
11.2.2. By Test Type
11.2.3. By End User
11.2.4. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Newborn Screening Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Technology
11.3.1.2.2. By Test Type
11.3.1.2.3. By End User
11.3.2. Saudi Arabia Newborn Screening Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Technology
11.3.2.2.2. By Test Type
11.3.2.2.3. By End User
11.3.3. UAE Newborn Screening Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Technology
11.3.3.2.2. By Test Type
11.3.3.2.3. By End User
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
13.1. Recent Developments
13.2. Product Launches
13.3. Mergers & Acquisitions
14. GLOBAL NEWBORN SCREENING MARKET: SWOT ANALYSIS
15. PORTER’S FIVE FORCES ANALYSIS
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Product
16. PESTLE ANALYSIS
17. COMPETITIVE LANDSCAPE
17.1. Bio-Rad Laboratories Inc.
17.1.1. Business Overview
17.1.2. Company Snapshot
17.1.3. Products & Services
17.1.4. Financials (As Reported)
17.1.5. Recent Developments
17.1.6. Key Personnel Details
17.1.7. SWOT Analysis
17.2. GE Healthcare
17.3. Masimo Corporation
17.4. Medtronic Inc.
17.5. Natus Medical Incorporated
17.6. PerkinElmer Inc.
17.7. Trivitron Healthcare
17.8. ZenTech SA
17.9. Demant A/S
17.10. Hill-Rom Holdings Inc.
18. STRATEGIC RECOMMENDATIONS
19. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. IMPACT OF COVID-19 ON GLOBAL NEWBORN SCREENING MARKET
5. VOICE OF CUSTOMER
6. GLOBAL NEWBORN SCREENING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology (Tandem Mass Spectrometry, Pulse Oximetry, Enzyme Based Assays, DNA Assays, and Other Technologies)
6.2.2. By Test Type (Dried Blood Spot, Hearing Screening, Critical Congenital Heart Defect (CCHD), and Other Test Types)
6.2.3. By End User (Hospitals, Diagnostic Centers, and Other End Users),
6.2.4. By Region
6.2.5. By Company (2024)
6.3. Market Map
7. ASIA PACIFIC NEWBORN SCREENING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Test Type
7.2.3. By End User
7.2.4. By Country
7.3. Asia Pacific: Country Analysis
7.3.1. China Newborn Screening Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Test Type
7.3.1.2.3. By End User
7.3.2. India Newborn Screening Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Test Type
7.3.2.2.3. By End User
7.3.3. Australia Newborn Screening Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Test Type
7.3.3.2.3. By End User
7.3.4. Japan Newborn Screening Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Test Type
7.3.4.2.3. By End User
7.3.5. South Korea Newborn Screening Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Test Type
7.3.5.2.3. By End User
8. EUROPE NEWBORN SCREENING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Test Type
8.2.3. By End User
8.2.4. By Country
8.3. Europe: Country Analysis
8.3.1. France Newborn Screening Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Test Type
8.3.1.2.3. By End User
8.3.2. Germany Newborn Screening Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Test Type
8.3.2.2.3. By End User
8.3.3. Spain Newborn Screening Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Test Type
8.3.3.2.3. By End User
8.3.4. Italy Newborn Screening Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Test Type
8.3.4.2.3. By End User
8.3.5. United Kingdom Newborn Screening Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Test Type
8.3.5.2.3. By End User
9. NORTH AMERICA NEWBORN SCREENING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Test Type
9.2.3. By End User
9.2.4. By Country
9.3. North America: Country Analysis
9.3.1. United States Newborn Screening Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Test Type
9.3.1.2.3. By End User
9.3.2. Mexico Newborn Screening Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Test Type
9.3.2.2.3. By End User
9.3.3. Canada Newborn Screening Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Test Type
9.3.3.2.3. By End User
10. SOUTH AMERICA NEWBORN SCREENING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Test Type
10.2.3. By End User
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Newborn Screening Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Test Type
10.3.1.2.3. By End User
10.3.2. Argentina Newborn Screening Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Test Type
10.3.2.2.3. By End User
10.3.3. Colombia Newborn Screening Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Test Type
10.3.3.2.3. By End User
11. MIDDLE EAST AND AFRICA NEWBORN SCREENING MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Technology
11.2.2. By Test Type
11.2.3. By End User
11.2.4. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Newborn Screening Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Technology
11.3.1.2.2. By Test Type
11.3.1.2.3. By End User
11.3.2. Saudi Arabia Newborn Screening Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Technology
11.3.2.2.2. By Test Type
11.3.2.2.3. By End User
11.3.3. UAE Newborn Screening Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Technology
11.3.3.2.2. By Test Type
11.3.3.2.3. By End User
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
13.1. Recent Developments
13.2. Product Launches
13.3. Mergers & Acquisitions
14. GLOBAL NEWBORN SCREENING MARKET: SWOT ANALYSIS
15. PORTER’S FIVE FORCES ANALYSIS
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Product
16. PESTLE ANALYSIS
17. COMPETITIVE LANDSCAPE
17.1. Bio-Rad Laboratories Inc.
17.1.1. Business Overview
17.1.2. Company Snapshot
17.1.3. Products & Services
17.1.4. Financials (As Reported)
17.1.5. Recent Developments
17.1.6. Key Personnel Details
17.1.7. SWOT Analysis
17.2. GE Healthcare
17.3. Masimo Corporation
17.4. Medtronic Inc.
17.5. Natus Medical Incorporated
17.6. PerkinElmer Inc.
17.7. Trivitron Healthcare
17.8. ZenTech SA
17.9. Demant A/S
17.10. Hill-Rom Holdings Inc.
18. STRATEGIC RECOMMENDATIONS
19. ABOUT US & DISCLAIMER
